ROYALTY PHARMA PLC- CL A (RPRX)

GB00BMVP7Y09 - Common Stock

31.185  -0.05 (-0.14%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
2.122B
16.98%
2.29B
7.87%
2.237B
-2.28%
2.835B
26.72%
N/AN/AN/AN/A
EBITDA
YoY % growth
N/AN/AN/A2.791B
EBIT
YoY % growth
1.661B
-36.70%
1.431B
-13.84%
922.9M
-35.49%
2.162B
134.26%
N/AN/AN/AN/A
Operating Margin
78.24%62.49%41.25%76.26%N/AN/AN/AN/A
EPS
YoY % growth
N/A2.233.67
64.57%
4.07
11.01%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
1.03
-33.96%
Revenue
Q2Q % growth
705.48M
24.71%
N/AN/AN/AN/A
EBITDA
Q2Q % growth
649.14M
EBIT
Q2Q % growth
356.82M
168.08%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
1.15
-26.28%
1.030.1211.63%
Q3 2023
Q2Q % growth
0.79
9.72%
0.770.022.45%
Q2 2023
Q2Q % growth
0.84
6.33%
0.820.021.92%
Q1 2023
Q2Q % growth
1.60
166.67%
1.300.3023.19%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
536.3M
-6.49%
630.35M-94.05M-14.92%
Q2 2023
Q2Q % growth
538.2M
0.41%
547.32M-9.12M-1.67%
Q1 2023
Q2Q % growth
684M
21.71%
869.96M-185.96M-21.38%
Q4 2022
Q2Q % growth
565.7M
-1.74%
970.32M-404.62M-41.70%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% -4.71% -3.4%
Revenue0% 0% -2.44% -2.41%